Inhibitor Therapeutics (INTI) Cash from Financing Activities (2013 - 2023)
Inhibitor Therapeutics' (INTI) quarterly Cash from Financing Activities came in at -$411000.0 in Q1 2023, down 922.0% YoY from $50000.0 in Q1 2022, and down 613.75% on a QoQ basis from $80000.0 in Q3 2022.
Inhibitor Therapeutics (INTI) Cash from Financing Activities (2013 - 2023) Analysis & Trends
Inhibitor Therapeutics (INTI) has 10 years of Cash from Financing Activities data on file, last reported at -$411000.0 in Q1 2023.
- Quarterly Cash from Financing Activities fell 922.0% year-over-year to -$411000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was -$411000.0 (down 328.33% YoY) and the FY2023 annual result came in at -$411000.0, down 328.33% from the prior year.
- Cash from Financing Activities declined to -$411000.0 in Q1 2023, from $80000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $1.5 million in Q2 2019 to a low of -$411000.0 in Q1 2023.
- A 5-year average of $222038.4 and a median of $55000.0 in 2020 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2019 — Cash from Financing Activities surged 12400.0% — and 2023, when it slumped 922.0%.
- Tracing INTI's Cash from Financing Activities over 5 years: stood at -$99178.0 in 2019, then soared by 155.46% to $55000.0 in 2020, then soared by 36.36% to $75000.0 in 2021, then advanced by 6.67% to $80000.0 in 2022, then sank by 613.75% to -$411000.0 in 2023.
- The last three Cash from Financing Activities figures came in at -$411000.0 (Q1 2023), $80000.0 (Q3 2022), and $50000.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -411,000.00 |
| Mar 31, 2023 | -411,000.00 |
| Sep 30, 2022 | 80,000.00 |
| Sep 30, 2022 | 80,000.00 |
| Jun 30, 2022 | 50,000.00 |
| Jun 30, 2022 | 50,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Jun 30, 2021 | 75,000.00 |
| Jun 30, 2021 | 75,000.00 |
| Mar 31, 2021 | 101,000.00 |
| Mar 31, 2021 | 101,000.00 |
| Dec 31, 2020 | 55,000.00 |
| Dec 31, 2020 | 55,000.00 |
| Jun 30, 2020 | 41,600.00 |
| Jun 30, 2020 | 41,600.00 |
| Sep 30, 2019 | -99,178.00 |
| Sep 30, 2019 | -99,178.00 |
| Jun 30, 2019 | 1.50 Mn |
| Jun 30, 2019 | 1.50 Mn |